Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs > MD & A and Interim Financials Out

<< Previous

Bullboard Posts

Next >>

Comment by The300on Apr 19, 2011 8:00pm

188 Views

Post# 18457142

RE: RE: MD & A and Interim Financials Out

Hey Camaroni,

I agree with your assessment that we still have someone continuing to dump.

I've been told a few times in the past by various company reps that it is Dwek that continues to dump and am always told that "they are just about done selling", Not sure if that is the case. Unfortunately the sells are coming from a number of different houses and Dwek is no longer an insider so we can't track their sales on SEDI. At this point it is pure speculation.

What the company can do to help combat this is to market the company more effectively to have retail help support the market or arrange to have interested institutions cross out any remaining stock that Dwek has left (if it is infact Dwek).

As always, the above is IMHO

Regards,

The 300

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario